Treatment of Symptomatic Vitreomacular Adhesion with Expansile Sulfur Hexafluoride (SF6) Gas

Dominic M Buzzacco1, 2, *, Sugat S Patel2
1 Havener Eye Institute, The Ohio State University, 915 Olentangy River Road, Columbus, Ohio, 43212, USA
2 Midwest Retina, 6655 Post Road, Columbus, Ohio, 43016, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2255
Abstract HTML Views: 1977
PDF Downloads: 758
ePub Downloads: 564
Total Views/Downloads: 5554
Unique Statistics:

Full-Text HTML Views: 1230
Abstract HTML Views: 1052
PDF Downloads: 485
ePub Downloads: 333
Total Views/Downloads: 3100

Creative Commons License
© 2017 Buzzacco and Patel.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Midwest Retina, 6655 Post Road, Dublin, Oh 43016, USA; Tel: 614-339-8500; Fax: 614-339-8501; E-mail:



To evaluate intravitreal injection of expansile sulfur hexafluoride (SF6) as a low cost and effective treatment for symptomatic vitreomacular adhesion (sVMA).


Retrospective analysis of all patients with sVMA treated with pneumatic vitreolysis using SF6 gas presenting to a clinical practice from January 2005 and June 2013.


Six cases were included in the study. Five patients (83%) experienced complete resolution of the vitreomacular adhesion. One patient had a partial release of the vitreomacular adhesion. Four patients (67%) had a one line improvement in best corrected visual acuity.


Due to its low cost, wide availability, and apparent efficacy, intravitreal injection of expansile SF6 should be investigated further as a possible treatment modality for sVMA.

Keywords: Intravitreal, Vitreomacular, Adhesion, Expansile, Diabetes, Sulphur hexaflouride.